Bio-Path Holdings, Inc. (BPTH)
After hours:
| Previous close | 2.9500 |
| Open | 2.8800 |
| Bid | 2.1600 x 200 |
| Ask | 3.6400 x 200 |
| Day's range | 2.7050 - 3.1499 |
| 52-week range | 2.7050 - 44.8000 |
| Volume | |
| Avg. volume | 27,796 |
| Market cap | 2.299M |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -33.6300 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.00 |
GlobeNewswireBio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio. Bi
- GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several MilestonesHOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. “The new year is off to a strong start as we build off positive data generated in 2023 that compel us to advanc
Insider MonkeyBio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript March 8, 2024 Bio-Path Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. […]
